Criteria of metabolic disorders in the prediction of gestational diabetes mellitus: analytical review
AbstractGestational diabetes mellitus (GDM) is associated with adverse maternal and fetal outcomes, as well as with the subsequent risk of developing diabetes mellitus and several other diseases. Modern methods for diagnosing GDM detect the disease when pancreatic β-cell insufficiency has already developed. Such late diagnosis exposes the pregnant woman and the fetus to the risk of various complications. Clinicians recognize that early diagnosis, adequate treatment, and careful follow-up are essential to reduce the incidence of GDM complications. Metabolomics, which is a platform used to analyze and characterize a large number of metabolites, is increasingly being used to study the pathophysiology of metabolic conditions such as GDM. The presented analytical review aims to summarize studies of metabolites in GDM.
Keywords:gestational diabetes mellitus; biomarker; metabolomics
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. Collection and analysis of literature data – Gazaryan L.G., Anikeev A.S.; writing the text of the article – Ghazaryan L.G.; editing the manuscript text – Neshcherova E.V., Anikeev A.S., Kulieva A.G.; development of the concept of the article – Ordiyants I.M.; verification of critical content – Ordiyants I.M., Startseva N.M., Neshcherova E.V., Kulieva A.G.; approval of the manuscript for publication – Ordiyants I.M., Startseva N.M. All authors made significant contributions to the preparation of the article and read and approved the final version before publication.
For citation: Gazaryan L.G., Ordiyants I.M., Startseva N.M., Anikeev A.S., Neshcherova E.V., Kulieva A.G. Criteria of metabolic disorders in the prediction of gestational diabetes mellitus: analytical review. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2024; 12. Supplement: 148–56. DOI: https://doi.org/10.33029/2303-9698-2024-12-suppl-148-156 (in Russian)
REFERENCES
1. Li L.-J., Wang X., Chong Y.S., et al. Exploring preconception signatures of metabolites in mothers with gestational diabetes mellitus using a non-targeted approach. BMC Med. 2023; 21 (1): 99.
2. Early pregnancy. From pre-pregnancy preparation to healthy gestation. 3rd ed., revised and additional. In: V.E. Radzinsky, A.A. Orazmuradov. Moscow: StatusPraesens, 2020: 800 p. (in Russian)
3. Papysheva O.V., Kotaysh G.A., Lukanovskaya O.B., et al. Gestational diabetes mellitus another mask of metabolic syndrome? Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2019; 7 (3): 32–7. (in Russian)
4. Predictive obstetrics. In: V.E. Radzinsky, S.A. Knyazev, I.N. Kostin (eds). Moscow: StatusPraesens, 2021: 520 p. (in Russian)
5. Bianco M.E., Josefson J.L. Hyperglycemia during pregnancy and long-term offspring outcomes. Curr Diabetes Rep. 2019; 19 (12): 143.
6. Ramezani Tehrani F., Farzadfar F., Hosseinpanah F., et al. Does fasting plasma glucose values 5.1-5.6 mmol/l in the first trimester of gestation a matter? Front Endocrinol. 2023; 14: 1155007.
7. Nakanishi S., Aoki S., Kasai J., et al. Non-efficacy of early intervention strategy for non-obese patients with early-onset gestational diabetes mellitus: solely based on the short-term outcomes. BMJ Open Diabetes Res Care. 2023; 11 (3): e003230.
8. Boriboonhirunsarn D., Sunsaneevithayakul P., Pannin C., et al. Prevalence of early-onset GDM and associated risk factors in a university hospital in Thailand. J Obstet Gynaecol. 2021; 41: 915–9.
9. Nicholson J.K., Lindon J.C., Holmes E. «Metabonomics»: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999; 29 (11): 1181–9.
10. Wang Q.-Y., You L.-H., Xiang L.-L., et al. Current progress in metabolomics of gestational diabetes mellitus. World J Diabetes. 2021; 12 (8): 1164–86.
11. Chen Q., Francis E., Hu G., et al. Metabolomic profiling of women with gestational diabetes mellitus and their offspring: review of metabolomics studies. J Diabetes Complications. 2018; 32 (5): 512–23.
12. Pinu F.R., Goldansaz S.A., Jaine J. Translational metabolomics: current challenges and future opportunities. Metabolites. 2019; 9 (6): 108.
13. Liang L., Rasmussen M.-L.H., Piening B., et al. Metabolic dynamics and prediction of gestational age and time to delivery in pregnant women. Cell. 2020; 181 (7): 1680–92.e15.
14. Anh N.H., Long N.P., Kim S.J., et al. Steroidomics for the prevention, assessment, and management of cancers: a systematic review and functional analysis. Metabolites. 2019; 9 (10): 199.
15. Priante E., Verlato G., Giordano G., et al. Intrauterine growth restriction: new insight from the metabolomic approach. Metabolites. 2019; 9 (11): 267.
16. Shi X., Xi B., Jasbi P., et al. Comprehensive isotopic targeted mass spectrometry: reliable metabolic flux analysis with broad coverage. Anal Chem. 2020; 92 (17): 11 728–38.
17. Jang W.-J., Choi J.Y., Park B., et al. Hair metabolomics in animal studies and clinical settings. Molecules. 2019; 24 (12): 2195.
18. Klepacki J., Klawitter J., Klawitter J., et al. Amino acids in a targeted versus a non-targeted metabolomics LC-MS/MS assay. Are the results consistent? Clin Biochem. 2016; 49 (13–14): 955–61.
19. Au A., Cheng K.-K., Wei L.K. Metabolomics, lipidomics and pharmacometabolomics of human hypertension. In: Md.S. Islam (ed.). Hypertension: from Basic Research to Clinical Practice (Book series: Advances in Experimental Medicine and Biology). Cham: Springer International Publishing, 2016; 956: 599–613.
20. Tsiropoulou S., McBride M., Padmanabhan S. Urine metabolomics in hypertension research. In: R.M. Touyz, E.L. Schiffrin (eds). Hypertension (Book series: Methods in Molecular Biology). New York: Springer, 2017; 1527: 61–8.
21. Wishart D.S., Feunang Y.D., Marcu A., et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 2018; 46 (D1): D608–17.
22. Khodadadi M., Pourfarzam M. A review of strategies for untargeted urinary metabolomic analysis using gas chromatography-mass spectrometry. Metabolomics. 2020; 16 (6): 66.
23. Mediani A., Baharum S.N. Metabolomics: challenges and opportunities in systems biology studies. In: Methods in Molecular Biology. New York: Springer, 2024; 2745: 77–90.
24. Zhang A., Sun H., Yan G., et al. Mass spectrometry-based metabolomics: applications to biomarker and metabolic pathway research. Biomed Chromatogr. 2016; 30 (1): 7–12.
25. Mokkala K., Vahlberg T., Houttu N., et al. Distinct metabolomic profile because of gestational diabetes and its treatment mode in women with overweight and obesity. Obesity. 2020; 28 (9): 1637–44.
26. Iacobazzi V., Infantino V. Citrate – new functions for an old metabolite. Biol Chem. 2014; 395 (4): 387–99.
27. Gralka E., Luchinat C., Tenori L., et al. Metabolomic fingerprint of severe obesity is dynamically affected by bariatric surgery in a procedure-dependent manner. Am J Clin Nutr. 2015; 102 (6): 1313–22.
28. Lai M., Liu Y., Ronnett G.V. Amino acid and lipid metabolism in post-gestational diabetes and progression to type 2 diabetes: a metabolic profiling study. PLoS Med. 2020; 17 (5): e1003112.
29. Zeng Z., Liu F., Li S. Metabolic adaptations in pregnancy: a review. Ann Nutr Metab. 2017; 70 (1): 59–65.
30. Bronisz A., Ozorowski M., Hagner-Derengowska M. Pregnancy ketonemia and development of the fetal central nervous system. Int J Endocrinol. 2018; 2018: 1–7.
31. Qiu C., Enquobahrie D.A., Frederick I.O., et al. Early pregnancy urinary biomarkers of fatty acid and carbohydrate metabolism in pregnancies complicated by gestational diabetes. Diabetes Res Clin Pract. 2014; 104 (3): 393–400.
32. Heath H., Rosario R., McMichael L.E., et al. Gestational diabetes is characterized by decreased medium-chain acylcarnitines and elevated purine degradation metabolites across pregnancy: a case-control time-course analysis. J. Proteome Res. 2023; 22 (6): 1603–13.
33. Papachristoforou E., Lambadiari V., Maratou E., et al. Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. J Diabetes Res. 2020; 2020: 7489795.
34. Enquobahrie D.A., Denis M., Tadesse M.G., et al. Maternal early pregnancy serum metabolites and risk of gestational diabetes mellitus. J Clin Endocrinol Metab. 2015; 100 (11): 4348–56.
35. Felig P., Marliss E., Cahill G.F. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med. 1969; 281 (15): 811–6.
36. Holeček M. Role of impaired glycolysis in perturbations of amino acid metabolism in diabetes mellitus. Int J Mol Sci. 2023; 24 (2): 1724.
37. White S.L., Pasupathy D., Sattar N., et al. Metabolic profiling of gestational diabetes in obese women during pregnancy. Diabetologia. 2017; 60 (10): 1903–12.
38. Bentley-Lewis R., Huynh J., Xiong G., et al. Metabolomic profiling in the prediction of gestational diabetes mellitus. Diabetologia. 2015; 58 (6): 1329–32.
39. Nevalainen J., Sairanen M., Appelblom H., et al. First-trimester maternal serum amino acids and acylcarnitines are significant predictors of gestational diabetes. Rev Diabet Stud. 2016; 13 (4): 236–45.
40. Sakurai K., Eguchi A., Watanabe M., et al. Exploration of predictive metabolic factors for gestational diabetes mellitus in Japanese women using metabolomic analysis. J Diabetes Investig. 2019; 10 (2): 513–20.
41. Leitner M., Fragner L., Danner S., et al. Combined metabolomic analysis of plasma and urine reveals AHBA, tryptophan and serotonin metabolism as potential risk factors in gestational diabetes mellitus (GDM). Front Mol Biosci. 2017; 4: 84.
42. Roy C., Tremblay P.-Y., Anassour-Laouan-Sidi E., et al. Risk of gestational diabetes mellitus in relation to plasma concentrations of amino acids and acylcarnitines: a nested case-control study. Diabetes Res Clin Pract. 2018; 140: 183–90.
43. Auvinen A.-M., Luiro K., Jokelainen J., et al. Type 1 and type 2 diabetes after gestational diabetes: a 23-year cohort study. Diabetologia. 2020; 63 (10): 2123–8.
44. Andersson-Hall U., Gustavsson C., Pedersen A., et al. Higher concentrations of BCAAs and 3-HIB are associated with insulin resistance in the transition from gestational diabetes to type 2 diabetes. J Diabetes Res. 2018; 2018: 1–12.
45. Li N., Cen Z., Zhao Z., et al. BCAA dysmetabolism in the host and gut microbiome, a key player in the development of obesity and T2DM. Med Microecol. 2023; 16: 100078.
46. White P.J., McGarrah R.W., Herman M.A., et al. Insulin action, type 2 diabetes, and branched-chain amino acids: a two-way street. Mol Metab. 2021; 52: 101261.
47. Ruze R., Liu T., Zou X., et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023; 14: 1161521.
48. Xie J., Li L., Xing H. Metabolomics in gestational diabetes mellitus: a review. Clin Chim Acta. 2023; 539: 134–43.
49. Bukowiecka-Matusiak M., Burzynska-Pedziwiatr I., Sansone A., et al. Lipid profile changes in erythrocyte membranes of women with diagnosed GDM. PLoS One. 2018; 13 (9): e0203799.
50. Petry C.J., Ong K.K., Dunger D.B. Does the fetal genotype affect maternal physiology during pregnancy? Trends Mol Med. 2007; 13 (10): 414–21.
51. Hocher B., Chen Y.-P., Schlemm L., et al. Fetal sex determines the impact of maternal PROGINS progesterone receptor polymorphism on maternal physiology during pregnancy. Pharmacogenet Genomics. 2009; 19 (9): 710–8.
52. Hocher B., Schlemm L., Haumann H., et al. Interaction of maternal peroxisome proliferator-activated receptor gamma2 Pro12Ala polymorphism with fetal sex affects maternal glycemic control during pregnancy. Pharmacogenet Genomics. 2010; 20 (2): 139–42.
53. Hocher B., Schlemm L., Haumann H., et al. Offspring sex determines the impact of the maternal ACE I/D polymorphism on maternal glycaemic control during the last weeks of pregnancy. J Renin Angiotensin Aldosterone Syst (JRAAS). 2011; 12 (3): 254–61.
54. Petry C.J., Seear R.V., Wingate D.L., et al. Associations between paternally transmitted fetal IGF2 variants and maternal circulating glucose concentrationsin pregnancy. Diabetes. 2011; 60 (11): 3090–6.
55. Petry C.J., Beardsall K., Dunger D.B. The potential impact of the fetal genotype on maternal blood pressure during pregnancy. J Hypertens. 2014; 32 (8): 1553–61.
56. Ronco A., Roero S., Arduino S., et al. Gestational diabetes mellitus does not worsen obstetrical and neonatal outcomes of twin pregnancy. J Clin Med. 2023; 12 (9): 3129.
57. Peng S., Zhang J., Liu L., et al. Newborn meconium and urinary metabolome response to maternal gestational diabetes mellitus: a preliminary case-control study. J Proteome Res. 2015; 14 (4): 1799–809.
58. Mokkala K., Vahlberg T., Pellonperä O., et al. Distinct metabolic profile in early pregnancy of overweight and obese women developing gestational diabetes. J Nutr. 2020; 150 (1): 31–7.
59. He X.-L., Hu X.-J., Luo B.-Y., et al. The effects of gestational diabetes mellitus with maternal age between 35 and 40 years on the metabolite profiles of plasma and urine. BMC Pregnancy Childbirth. 2022; 22 (1): 174.
60. Roverso M., Dogra R., Visentin S., et al. Mass spectrometry-based «omics» technologies for the study of gestational diabetes and the discovery of new biomarkers. Mass Spectrom Rev. 2023; 42 (4): 1424–61.